RDIF has agreed to produce 200 million doses of Sputnik V in India

The Russian Direct Investment Fund (RDIF) has agreed to produce 200 million doses of Sputnik V in India. A contract was signed with Stelis Biopharma (the biopharmaceutical division of Strides Holding, one of the world's leading pharmaceutical companies headquartered in India). This was announced on March 19, 2021.

The agreement between RDIF and Stelis Biopharma was concluded with the support of Enso Healthcare LLP (a division of Enso Group), an RDIF partner in attracting contract sites for vaccine production in India.

The parties intend to begin deliveries of Sputnik V in the third quarter of 2021. Stelis will also continue to work with RDIF to ensure additional supply volumes beyond the original agreement. The fund specified that thanks to the contract, 100 million people will be vaccinated.

RDIF has agreed to produce 200 million doses of Sputnik V in India

Commenting on the conclusion of the partnership agreement, the head of the RDIF, Kirill Dmitriev, called Sputnik V one of the best coronavirus vaccines in the world. According to him, the joint production of the drug with Stelis will increase its availability around the world.

We are pleased to cooperate with the RDIF, which will make a significant contribution to ensuring the global supply of Sputnik V vaccine, one of the most effective vaccines available on the market. We will also work with the RDIF to increase the availability of the vaccine beyond our initial obligations, "said Arun Kumar, founder of the Strides Group, whose words are quoted by the RDIF press service.

By March 2021, contracts for the mass production of the Sputnik V vaccine were signed with 15 manufacturers in 10 countries. They should produce 1.4 billion doses of a two-component vaccine, which can be vaccinated 700 million people. In particular, we are talking about companies from China, India, Iran, South Korea, Brazil and Serbia.^[1]

Notes